Skip to content
Screener

Vertex Pharmaceuticals VRTX Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$3.3BBeat by $103.3M
Adjusted EPS$4.73Miss by $0.01
Revenue estimate$3.2B
EPS estimate$4.74
“With this breadth of commercial and clinical opportunities, we look forward to bringing more medicines to more patients around the globe and in so doing, creating long-term value.”
Reshma Kewalramani

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.

Next report

Nov 2, 2026 (in a month)
Revenue estimate$3.4B
EPS estimate$4.76

Financials

Q2 2026

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$128.44B+22.5%
Enterprise value$122.56B+20.5%
P/E29.2×—
P/S10.2×+1.3×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%—
Net margin35%—

Returns & leverage

See full
Return on equity23.5%—
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Segments

By product

See full
TRIKAFTA/KAFTRIO$2.5B-2.1%
ALYFTREK$573.6M+266%
CASGEVY$76.4M—
JOURNAVX$49.6M—

FAQ

When did Vertex Pharmaceuticals report Q2 2026 earnings?
Vertex Pharmaceuticals (VRTX) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Vertex Pharmaceuticals's Q2 2026 revenue and EPS?
Vertex Pharmaceuticals reported revenue of $3.3B and adjusted eps of $4.73 for Q2 2026.
Did Vertex Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $3.2B by $103.3M. EPS missed the consensus estimate of $4.74 by $0.01.
How did Vertex Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.5% from $3.0B a year earlier.
Where can I find Vertex Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000875320-26-000256) and the 10-Q periodic report (0000875320-26-000259) directly on SEC EDGAR. The filing index links above go to sec.gov.